-
Belviq Recall: FDA Warning Cancer Risks Of Diet Drug Belviq Outweigh Benefits — February 2020
Excess Cases Of Pancreatic Cancer, Colon Cancer, Rectal Cancer, And Lung Cancer Observed In Belviq Safety Clinical Trial (Posted by Tom Lamb at DrugInjuryWatch.com) On February 13, 2020 the FDA requested Eisai…
-
Hypophosphatemia As A Side Effect Of Injectafer vs. Monoferric Treatments: Comparisons From Two Clinical Trials
New JAMA Medical Journal Article Reports A Significant Higher Hypophosphatemia Incidence Rate With Injectafer Compared To Monoferric (Posted by Tom Lamb at DrugInjuryWatch.com) In this earlier article, “Injectafer-Induced Hypophosphatemia Can Be A…
-
Injectafer-Induced Hypophosphatemia Can Be A Serious Side Effect Of This Iron Deficiency Anemia Drug
Hypophosphatemia Is An Injectafer Side Effect With Possible Medical Complications Leading To Hospitalization Or Death (Posted by Tom Lamb at DrugInjuryWatch.com) Injectafer (ferric carboxymaltose) is an iron replacement injection approved by the…
-
Picato Skin Cancer Risk Investigation By European Drug Regulator Prompts Sales Suspension In Europe
January 2020 News Report: FDA “is gathering data and information to investigate the safety concern related to Picato” (Posted by Tom Lamb at DrugInjuryWatch.com) UPDATE: The UK’s Medicines and Health products Regulatory…
-
Acute Renal Failure With Uloric Reported Almost 6 Times More Frequently Compared To Some Other Gout Drugs
Uloric-Related Acute Kidney Injury: Researchers Find A Significantly Higher Reporting Odds Ratio In Women Compared To Men (Posted by Tom Lamb at DrugInjuryWatch.com) Uloric (febuxostat) is a popular urate-lowering therapy (ULT) used…
-
Belviq Cancer Risk Warning Alert Issued To Patients And Doctors In January 2020 FDA Drug Safety Communication
Recent Clinical Trial Findings Suggest Use Of The Weight-Loss Medicine Belviq Increased Risk Of Cancers (Posted by Tom Lamb at DrugInjuryWatch.com) UPDATE: "FDA requests the withdrawal of the weight-loss drug Belviq, Belviq…
